(32) reported that treatment of bladder cancer cells with cetuximab inhibited CD46 expression and subsequently promoted both CDC and ADCC, which might be a beneficial mechanism of mAb immunotherapy for cancer treatment. This evidence concerns the gene CD46 and urinary bladder carcinoma.